title: Adult-specific systemic over-expression reveals novel in vivo effects of the soluble forms of ActRIIA, ActRIIB and BMPRII.
abstract: Bone morphogenetic proteins (BMPs)/growth differentiation factors (GDFs), which belong to the TGF-beta superfamily, are pleiotropic factors that play a role in regulating the embryonic development and postnatal homeostasis of various organs and tissues by controlling cellular differentiation, proliferation and apoptosis. Conventional transgenic and knockout (KO) mouse approaches have provided only limited information regarding the in vivo functions of BMP signaling in adult animals due to the effects on prenatal development and the difficulty in manipulating multiligand signals simultaneously. We recently produced transgenic chimeric mice(Tg chimeras) in which the soluble IgG1-Fc fusion protein of three BMP type II receptors (ActRIIA, ActRIIB, BMPRII) was highly circulated (281-709 μg/ml), specifically in adult mouse blood. Since each BMP receptor can bind to multiple BMP ligands, these Tg chimeras should be useful to investigate the effects of trapping multiple BMP ligands. Remarkably, some phenotypes were unexpected based on previous studies, such as KO mouse analyses, presumably representing the effects of the multiple ligand trapping. These phenotypes included increased red blood cells (RBCs) and decreased viability in adults. In a further study, we focused on the phenotype of increased RBCs and found that extramedullary hematopoiesis in the spleen, not in the bone marrow, was increased using histological and flow cytometric analyses. Although it remains to be elucidated whether the transgene products affect the tissues directly or indirectly, our data provide novel and important insight into the biological functions of the soluble IgG1-Fc fusion protein of three BMP type II receptors in adults, and our approach should have broad applications to research on other ligand receptor families and studies involving mouse models.
authors.affiliation: Biologics Research Laboratories, Kyowa Hakko Kirin Co., Ltd, Machida-shi, Tokyo, Japan.
authors.forename: Kengo
authors.initials: K
authors.lastname: Yamawaki
authors.forename: Shinobu
authors.initials: S
authors.lastname: Ueda
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Okada
authors.forename: Takeshi
authors.initials: T
authors.lastname: Oshima
authors.forename: Makoto
authors.initials: M
authors.lastname: Kakitani
authors.forename: Takashi
authors.initials: T
authors.lastname: Kato
authors.forename: Kazuma
authors.initials: K
authors.lastname: Tomizuka
mesh_terms: D030301:Activin Receptors, Type II / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D052006:Bone Morphogenetic Protein Receptors, Type II / Q000235:genetics / Q000378:metabolism*; D004912:Erythrocytes / Q000378:metabolism; D004921:Erythropoietin / Q000235:genetics / Q000378:metabolism; D005434:Flow Cytometry; D006801:Humans; D018345:Mice, Knockout; D008822:Mice, Transgenic
chemical_list: C554270:EPO protein, human; D004921:Erythropoietin; D030301:Activin Receptors, Type II; D052006:Bone Morphogenetic Protein Receptors, Type II; C425584:activin receptor type II-B